Interchangeable Biosimilars: FDA Clarifies US Reference Not Mandatory For Studies
Draft guidance strongly recommends against it, but US FDA's Leah Christl says agency is willing to talk about using foreign-licensed comparators.
You may also be interested in...
Biosimilars: US FDA Education Campaign Is Non-Committal On Non-Medical Switching
Substituting a biosimilar for a reference product is a state issue and outside agency's purview, FDA says.
Biosimilar Firms Fight Against 'Whisper Campaign' On Interchangeability
Industry calls for more education amid concerns that brand sales reps are encouraging providers to use only interchangeable products because they are better than biosimilars.
Humira Biosimilar Interchangeability: The Race Begins
Boehringer Ingelheim announcement is first public disclosure of interchangeability trial since US FDA draft guidance was released.